ARTICLE | Company News
SuperGen, Abbott deal
January 4, 2000 8:00 AM UTC
ABT will exclusively market worldwide SUPG's rubitecan (RFS 2000) oral chemotherapy compound, which is in Phase III testing to treat pancreatic cancer (see BioCentury Extra, Dec. 23, 1999). The compan...